poisar

Stocks · News reference

Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $20

Benzinga Newsdesk

Barclays analyst Glen Santangelo maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $16 to $20.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

AMRX
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?

    Amneal Pharmaceuticals shares surged 8.6% following completion of its Kashiv BioSciences acquisition, creating an integrated biosimilars platform. However, consensus EPS estimates were revised 23.1% lower over the past month, which could limit future gains. Ionis Pharmaceuticals declined 5.1% with unchanged negative EPS expectations.

    AMRXIONS